Ocugen saw the highest growth of 1.99% in patent filings and no patents were granted in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Ocugen‘s patent filings and grants. Buy the databook here.
Ocugen has been focused on protecting inventions in United States(US) with one publication in Q2 2024
The United States(US) Patent Office dominates the patent filings with nearly 50% of filings. The United States(US), and World Intellectual Property Organization(WIPO) patent Office are among the top ten patent offices where Ocugen is filings its patents..
Smith & Nephew and Implantica Patent could be the strongest competitors for Ocugen
Patents related to cell & gene therapy and nanomedicine lead Ocugen's portfolio
Ocugen has the highest number of patents in cell & gene therapy followed by, nanomedicine and rare diseases. For cell & gene therapy, nearly 33% of patents were filed and no patents were granted in Q2 2024.
Cerebellar ataxia related patents lead Ocugen portfolio followed by epilepsy, and parkinson's disease
Ocugen has highest number of patents in cerebellar ataxia followed by epilepsy, parkinson's disease, alzheimer's disease.
For comprehensive analysis of Ocugen's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.